FDA
-
-
-
-
-
-
-
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
-
-
-
-
-
-
-
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
-
-
-
-
-
-
-
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
-
-
-
-
-
-
-
Adaptive Biotechnologies (ADPT) Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ
-
-
-
-
-
-
-
Adaptive Announces Launch of Epic Integration for clonoSEQ®
-
-
-
-
-
-
-
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
-
-
-
-
-
-
-
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
-
334,279 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


